FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4293182026> ?p ?o ?g. }

• W4293182026 abstract "Background: Multiple targeted therapeutics are available for radioiodine-refractory differentiated thyroid cancer (RAIR-DTC), but it remains unclear which treatment is optimal to achieve long-term survival. Methods: A systematic search of the PubMed, Embase, and ClinicalTrials.gov databases was conducted to identify eligible randomized controlled trials (RCTs) comparing the efficacy and safety of targeted treatments for patients with RAIR-DTC from inception to April, 2022. Data were extracted by following the recommendations of the Preferred Reporting Items for Systematic Review and Meta-analysis guidelines. We calculated the odds ratio (OR) or hazard ratio (HR), its corresponding 95% credible intervals (CrI), and the surface under the cumulative ranking curve (SUCRA) to indicate ranking probability using Bayesian network meta-analyses. The primary outcome was progression-free survival (PFS). The secondary outcomes were overall survival (OS), objective response rate (ORR), disease control rate (DCR), and grade 3 or higher adverse events. Results: A total of 12 eligible RCTs involved 1,959 patients and 13 treatments: apatinib, cabozantinib, anlotinib, nintedanib, lenvatinib, lenvatinib with low dose (LD), sorafenib, sorafenib plus everolimus, donafenib (200 mg), donafenib (300 mg), pazopanib (continuous), pazopanib (intermittent), and vandetanib. Pooled analyses indicated that targeted therapeutics significantly prolonged PFS and OS in patients with RAIR-DTC (0.31, 0.21-0.41; 0.69, 0.53-0.85, respectively) compared with placebo. Network meta-analyses indicated that lenvatinib showed the most favorable PFS, with significant differences versus sorafenib (0.33, 0.23-0.48), vandetanib (0.31, 0.20-0.49), nintedanib (0.30, 0.15-0.60), and placebo (0.19, 0.15-0.25), while apatinib was most likely to be ranked first for prolonging OS with a SUCRA of 0.90. Lenvatinib showed the highest ORR (66%, 61%-70%), followed by anlotinib (59%, 48%-70%) and apatinib (54%, 40%-69%). Lenvatinib caused the most adverse events of grade 3 or higher, followed by lenvatinib (LD) and apatinib. Different toxicity profiles of individual treatment were also revealed. Conclusion: This network meta-analysis suggests that lenvatinib and apatinib were associated with the best progression-free survival and overall survival benefits, respectively, for patients with RAIR-DTC, compared with other targeted therapeutics. Patients who received lenvatinib or apatinib also had more grade 3 or higher adverse events. Systematic Review Registration: [https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=302249], identifier [CRD42022302249]." @default.
• W4293182026 created "2022-08-27" @default.
• W4293182026 creator A5003047664 @default.
• W4293182026 creator A5004557270 @default.
• W4293182026 creator A5025025666 @default.
• W4293182026 creator A5026143070 @default.
• W4293182026 creator A5030699547 @default.
• W4293182026 creator A5031639923 @default.
• W4293182026 creator A5056137322 @default.
• W4293182026 creator A5076175601 @default.
• W4293182026 creator A5081593622 @default.
• W4293182026 date "2022-08-26" @default.
• W4293182026 modified "2023-09-26" @default.
• W4293182026 title "Efficacy and safety of targeted therapeutics for patients with radioiodine-refractory differentiated thyroid cancer: Systematic review and network meta-analysis" @default.
• W4293182026 cites W1848939527 @default.
• W4293182026 cites W1967792499 @default.
• W4293182026 cites W1996403619 @default.
• W4293182026 cites W2017187984 @default.
• W4293182026 cites W2087614255 @default.
• W4293182026 cites W2111349551 @default.
• W4293182026 cites W2125435699 @default.
• W4293182026 cites W2145150141 @default.
• W4293182026 cites W2168076926 @default.
• W4293182026 cites W2503674037 @default.
• W4293182026 cites W2531346874 @default.
• W4293182026 cites W2781525129 @default.
• W4293182026 cites W2786390580 @default.
• W4293182026 cites W2787909081 @default.
• W4293182026 cites W2795875131 @default.
• W4293182026 cites W2891271941 @default.
• W4293182026 cites W2892376867 @default.
• W4293182026 cites W2946950110 @default.
• W4293182026 cites W2979271184 @default.
• W4293182026 cites W2996574710 @default.
• W4293182026 cites W3046155501 @default.
• W4293182026 cites W3080978633 @default.
• W4293182026 cites W3084285753 @default.
• W4293182026 cites W3108850818 @default.
• W4293182026 cites W3115626947 @default.
• W4293182026 cites W3163923489 @default.
• W4293182026 cites W3166329536 @default.
• W4293182026 cites W3166643980 @default.
• W4293182026 cites W3169956250 @default.
• W4293182026 cites W3179200118 @default.
• W4293182026 cites W3184438309 @default.
• W4293182026 cites W3196453900 @default.
• W4293182026 cites W3201577044 @default.
• W4293182026 cites W3201900523 @default.
• W4293182026 cites W4200167807 @default.
• W4293182026 cites W4226090961 @default.
• W4293182026 cites W4241786952 @default.
• W4293182026 cites W4294236195 @default.
• W4293182026 cites W80791343 @default.
• W4293182026 doi "https://doi.org/10.3389/fphar.2022.933648" @default.
• W4293182026 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36091770" @default.
• W4293182026 hasPublicationYear "2022" @default.
• W4293182026 type Work @default.
• W4293182026 citedByCount "3" @default.
• W4293182026 countsByYear W42931820262022 @default.
• W4293182026 countsByYear W42931820262023 @default.
• W4293182026 crossrefType "journal-article" @default.
• W4293182026 hasAuthorship W4293182026A5003047664 @default.
• W4293182026 hasAuthorship W4293182026A5004557270 @default.
• W4293182026 hasAuthorship W4293182026A5025025666 @default.
• W4293182026 hasAuthorship W4293182026A5026143070 @default.
• W4293182026 hasAuthorship W4293182026A5030699547 @default.
• W4293182026 hasAuthorship W4293182026A5031639923 @default.
• W4293182026 hasAuthorship W4293182026A5056137322 @default.
• W4293182026 hasAuthorship W4293182026A5076175601 @default.
• W4293182026 hasAuthorship W4293182026A5081593622 @default.
• W4293182026 hasBestOaLocation W42931820261 @default.
• W4293182026 hasConcept C121608353 @default.
• W4293182026 hasConcept C126322002 @default.
• W4293182026 hasConcept C143998085 @default.
• W4293182026 hasConcept C197934379 @default.
• W4293182026 hasConcept C207103383 @default.
• W4293182026 hasConcept C2776264508 @default.
• W4293182026 hasConcept C2778019345 @default.
• W4293182026 hasConcept C2778439243 @default.
• W4293182026 hasConcept C2778695046 @default.
• W4293182026 hasConcept C2779490328 @default.
• W4293182026 hasConcept C2779761222 @default.
• W4293182026 hasConcept C2780333294 @default.
• W4293182026 hasConcept C44249647 @default.
• W4293182026 hasConcept C71924100 @default.
• W4293182026 hasConcept C95190672 @default.
• W4293182026 hasConceptScore W4293182026C121608353 @default.
• W4293182026 hasConceptScore W4293182026C126322002 @default.
• W4293182026 hasConceptScore W4293182026C143998085 @default.
• W4293182026 hasConceptScore W4293182026C197934379 @default.
• W4293182026 hasConceptScore W4293182026C207103383 @default.
• W4293182026 hasConceptScore W4293182026C2776264508 @default.
• W4293182026 hasConceptScore W4293182026C2778019345 @default.
• W4293182026 hasConceptScore W4293182026C2778439243 @default.
• W4293182026 hasConceptScore W4293182026C2778695046 @default.
• W4293182026 hasConceptScore W4293182026C2779490328 @default.
• W4293182026 hasConceptScore W4293182026C2779761222 @default.
• W4293182026 hasConceptScore W4293182026C2780333294 @default.
• W4293182026 hasConceptScore W4293182026C44249647 @default.
• W4293182026 hasConceptScore W4293182026C71924100 @default.

• next